The diversity and clinical implications of genetic variants influencing clopidogrel bioactivation and response in the Emirati population.

ABSTRACT:

Background

Clopidogrel is a widely prescribed prodrug that requires activation via specific pharmacogenes to exert its anti-platelet function. Genetic variations in the genes encoding its transporter, metabolizing enzymes, and target receptor lead to variability in its activation and platelet inhibition and, consequently, its efficacy. This variability increases the risk of secondary cardiovascular events, and therefore, some variations have been utilized as genetic biomarkers when prescribing clopidogrel.

Methods

Our study examined clopidogrel-related genes (CYP2C19, ABCB1, PON1, and P2Y12R) in a cohort of 298 healthy Emiratis individuals. The study used whole exome sequencing (WES) data to comprehensively analyze pertinent variations of these genes, including their minor a

SUBMITTER: Khasawneh LQ 

PROVIDER: S-EPMC10765826 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature